Home/Filings/4/0000950170-24-028015
4//SEC Filing

Kalif Eliyahu Sharon 4

Accession 0000950170-24-028015

CIK 0000818686other

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 4:27 PM ET

Size

13.0 KB

Accession

0000950170-24-028015

Insider Transaction Report

Form 4
Period: 2024-03-05
Kalif Eliyahu Sharon
EVP, Chief Financial Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2024-03-05+52,320259,854 total
  • Exercise/Conversion

    Ordinary Shares

    2024-03-05+21,387281,241 total
  • Sale

    Ordinary Shares

    2024-03-06$13.52/sh77,550$1,048,119203,691 total
  • Exercise/Conversion

    Restricted Share Units

    2024-03-0521,38721,390 total
    Ordinary Shares (21,387 underlying)
  • Exercise/Conversion

    Restricted Share Units

    2024-03-0552,3200 total
    Ordinary Shares (52,320 underlying)
Footnotes (6)
  • [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
  • [F2]Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
  • [F3]The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 27, 2023.
  • [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.41 to $13.61, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
  • [F5]Restricted share units were granted on March 5, 2021, with 21,387 vesting on each of March 5, 2022, March 5, 2023, and March 5, 2024, and 21,390 vesting on March 5, 2025.
  • [F6]Restricted share units were granted on January 30, 2024 pursuant to the satisfaction of performance criteria and vested on March 5, 2024.

Documents

1 file

Issuer

TEVA PHARMACEUTICAL INDUSTRIES LTD

CIK 0000818686

Entity typeother

Related Parties

1
  • filerCIK 0001798443

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 4:27 PM ET
Size
13.0 KB